Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-12-01
2011-10-25
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S391100
Reexamination Certificate
active
08044181
ABSTRACT:
The current invention provides high-affinity antibodies to thePseudomonas aeruginosaPcrV protein that have reduced immunogenicity when administered to treatPseudomonas aeruginosainfections.
REFERENCES:
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5864019 (1999-01-01), King et al.
patent: 6815540 (2004-11-01), Pluckthun et al.
patent: 6818748 (2004-11-01), Fulton et al.
patent: 6827935 (2004-12-01), Frank et al.
patent: 7141393 (2006-11-01), Torigoe et al.
patent: 7294753 (2007-11-01), Kloetzer et al.
patent: 2005/0255552 (2005-11-01), Flynn et al.
patent: 2006/0134098 (2006-06-01), Bebbington et al.
patent: 2008/0108565 (2008-05-01), Winston, Jr. et al.
patent: WO 02/064161 (2002-08-01), None
patent: WO 2006/122822 (2006-11-01), None
patent: WO 2006/125481 (2006-11-01), None
patent: WO 2007/003010 (2007-01-01), None
patent: WO 2007/096396 (2007-08-01), None
patent: WO 2007/148417 (2007-12-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1982.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Chapman, A.P. et al.; “Therapeutic Antibody Fragments with Prolonged in Vivo Half-Lives”; 1999,Nature Biotechnology, vol. 17, No. 8, pp. 780-783.
Frank, D.W. et al.; “Generation and Characterization of a Protective Monoclonal Antibody toPseudomonas aeruginosaPerv”; 2002,Journal of Infectious Diseases, vol. 186, No. 1, pp. 64-73.
Humphreys, David P. et al.; “Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering”; 2007,Protein Engineering Design&Selection, vol. 20, No. 5, pp. 227-234.
Knight, David M. et al.; “Pharmacodynamic enhancement of the anti-platelet antibody Fab abciximab by site-specific pegylation”; 2004,Platelets, vol. 15, No. 7, pp. 409-418.
Baer Mark
Bebbington Christopher R.
Luehrsen Kenneth
Yarranton Geoffrey T.
Gussow Anne M.
KaloBios Pharmaceuticals, Inc.
Kilpatrick Townsend & Stockton LLP
LandOfFree
Antibodies to the PcrV antigen of Pseudomonas aeruginosa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to the PcrV antigen of Pseudomonas aeruginosa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to the PcrV antigen of Pseudomonas aeruginosa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255080